Larazotide Acetate vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
Larazotide AcetateFat Loss & Metabolic
AOD-9604- Summary
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- Local gut action; minimal systemic exposure
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Oral
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 0.5-2 mg
- 300-600 mcg
- Frequency
- 3x daily
- Once daily
- Key Benefits
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —